Insulet | PODD - Gross Profit On Sales


Insulet reported $540.8M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Abbott USD 5.86B 675M Mar/2026
Align Technology USD 736.59M 53M Mar/2026
AtriCure USD 109.31M 3.97M Mar/2026
Avanos Medical USD 94.2M 8.2M Mar/2026
Baxter International USD 891M 314M Mar/2026
Becton, Dickinson and Co. USD 2.15B 257M Mar/2026
Boston Scientific USD 3.61B 64M Mar/2026
Cardinal Health USD 2.5B 101M Mar/2026
Cooper Companies USD 735.4M 40.2M Mar/2026
Dexcom USD 750.3M 42.4M Mar/2026
Edwards Lifesciences USD 1.29B 59.4M Mar/2026
Eli Lilly USD 15.92B 1.33B Dec/2025
Globus Medical USD 496.26M 39.69M Mar/2026
ICU Medical USD 202.98M 2.1M Dec/2025
Inogen USD 41.34M 1.39M Sep/2024
Insulet USD 540.8M 27.8M Mar/2026
Integra LifeSciences USD 213.21M 3.89M Mar/2026
J&J USD 17.24B 642M Mar/2026
Masimo USD 250.8M 3.5M Mar/2026
Medtronic USD 6.01B 595M Mar/2026
Merit Medical Systems USD 184.8M 10.56M Mar/2026
Roche Holding CHF 22.09B 10.04B Dec/2025
Solventum Corp USD 1.1B 70M Mar/2026
Stryker USD 3.81B 675M Mar/2026
Tandem Diabetes Care USD 167.46M 33.17M Dec/2025
Teleflex USD 307.43M 21K Mar/2026
West Pharmaceutical Services USD 296.4M 7.5M Mar/2026
Zimmer Biomet Holdings USD 1.27B 8.1M Dec/2025